Naloxone hydrochloride is a Small Molecule owned by Emergent BioSolutions, and is involved in 8 clinical trials, of which 7 were completed, and 1 is ongoing.

Naloxone (LT-12) is an intranasal spray formulation of naloxone. It is an opioid antagonist which acts by acting on opioid receptors. Naloxone antagonizes opioid effects by competing for the mu, kappa and delta opiate receptor sites in the CNS, with the greatest affinity for the mu receptor. The endorphins bind to opioid receptors on other neurons and activate these opioid receptors, which reinforces the addictive behavior. LT-12 acts by blocking opioid receptors such as mu, kappa, and delta in the brain so endorphins are unable to exert their effects.

The revenue for Naloxone hydrochloride is expected to reach a total of $1.1bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Naloxone hydrochloride NPV Report.

Naloxone hydrochloride is currently owned by Emergent BioSolutions.

Naloxone hydrochloride Overview

Naloxone hydrochloride (Narcan) is a semi-synthetic morphine derivative acts as antidote. It is formulated as solution for  intravenous, intramuscular or subcutaneous route of administration, as aerosol spray for nasal route of administration. Narcan is indicated for the complete or partial reversal of opioid depression, including respiratory depression, induced by natural and synthetic opioids.

Naloxone hydrochloride (LT-12) was under development for the treatment of opioid overdose in the EU. It is administered intranasally as a nasal spray. The drug candidate is based on a patented technology. Naloxone is a opioid antagonist. It was also under development for binge eating disorder.

Emergent BioSolutions Overview

Emergent BioSolutions (Emergent) is a life sciences company that provides specialized products to address medical needs and public health threats (PHTs). Its solutions help address PHTs including chemical, biological, radiological, nuclear and explosives (CBRNE), emerging infectious diseases, travel health, emerging health crises, and acute/emergency care. It offers vaccines, therapeutics, drug-device combination products, and contract development and manufacturing services. Emergent‘s pipeline candidates target dengue and other influenza infections. It also offers specialized products to governments and commercial customers. The company distributes its products in the US and Canada through its commercial sales forces and third-party distributors. Emergent is headquartered in Rockville, Maryland, the US.

The company reported revenues of (US Dollars) US$1,792.7 million for the fiscal year ended December 2021 (FY2021), an increase of 15.3% over FY2020. In FY2021, the company’s operating margin was 19.7%, compared to an operating margin of 27.9% in FY2020. In FY2021, the company recorded a net margin of 12.9%, compared to a net margin of 19.6% in FY2020. The company reported revenues of US$240 million for the third quarter ended September 2022, a decrease of 1.1% over the previous quarter.

Quick View – Naloxone hydrochloride

Report Segments
  • Innovator (NME)
Drug Name
  • Naloxone hydrochloride
Administration Pathway
  • Intramuscular
  • Intravenous
  • Nasal
  • Subcutaneous
Therapeutic Areas
  • Central Nervous System
  • Toxicology
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.